{"success":true,"data":{"pressRelease":{"id":"111410","rtpr_id":"nGNX992kY2","ticker":"NUWE","exchange":"NASDAQ","all_tickers":["NUWE"],"title":"Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer","author":"Globe Newswire","published_at":"2026-08-06T12:30:00.743Z","article_body":"MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE),\na medical technology company committed to delivering solutions for patients\nwith cardiorenal conditions, today announced the appointment of Dale Brady as\nPrincipal R&D Engineer. Brady brings more than 25 years of medical device\nleadership experience in research and development, operations, manufacturing,\nquality systems and commercialization, with a proven track record of advancing\ninnovative products from concept through commercial launch. As Principal R&D\nEngineer, Brady joins Nuwellis’ research and development team to advance its\nexisting and new product development programs.\n\n\"Dale's experience developing innovative medical technologies from concept\nthrough commercialization makes him an outstanding addition to our\norganization,\" said Mike McCormick, Nuwellis President and Chief Executive\nOfficer. \"As we continue to expand our product development pipeline and\nexecute on multiple strategic initiatives, Dale brings the technical depth,\noperational discipline, and hands-on leadership that will help accelerate\ninnovation while maintaining our focus on quality and execution.\"\n\nThroughout Brady’s career, he has successfully led multidisciplinary\nengineering teams and developed products from initial concept through\nregulatory submission, manufacturing scale-up and commercial launch across\nboth venture-backed startups and publicly traded medical device companies.\nMost recently, Brady served on the executive leadership teams of Peytant\nSolutions and Endogenex, where he directed engineering and operations\nactivities supporting commercialization and clinical development.\n\nPreviously, Brady spent nearly a decade at Osprey Medical leading development\nof next-generation cardiovascular technologies and digital monitoring systems,\nand held engineering leadership positions at Anulex Technologies and\nSpine-Tech. He is also an inventor or co-inventor on 10 issued U.S. patents\nand 16 pending patent applications. Brady holds a Master of Science in\nEngineering Management from the University of Alaska Fairbanks and a Bachelor\nof Science in Mechanical Engineering from the University of Minnesota.\n\nKim Anderson, Nuwellis Vice President, Research & Development, Quality and\nOperations, added: \"Dale is a tremendous addition to our engineering\norganization. He has a unique combination of deep technical expertise and\npractical experience leading product development in both entrepreneurial\nmedical device companies and publicly traded organizations. He is an ideal fit\nfor Nuwellis given his ability and expertise to advance products from concept\nthrough commercialization, while working effectively in resource-constrained\nenvironments. Dale will play a key role in leading many of our internal\nproduct development initiatives and strengthening our ability to execute\nmultiple strategic programs simultaneously.”\n\nAbout Nuwellis\nNuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to\ndelivering solutions for patients with cardiorenal conditions. The Company\ndevelops solutions designed to support patient care through monitoring,\ntherapy, and data-informed clinical decision-making across acute and chronic\ncare settings. Nuwellis’ portfolio includes commercially available and\ndevelopment-stage technologies addressing complex cardiorenal conditions, with\na focus on safety, precision, and scalability across patient populations. For\nmore information, visit www.nuwellis.com.\n\nForward-Looking Statements\nCertain statements in this release may be considered forward-looking\nstatements within the meaning of the Private Securities Litigation Reform Act\nof 1995, including without limitation, statements regarding the new market\nopportunities and anticipated growth in 2026 and beyond. Forward-looking\nstatements are predictions, projections and other statements about future\nevents that are based on current expectations and assumptions and, as a\nresult, are subject to risks and uncertainties. Many factors could cause\nactual future events to differ materially from the forward-looking statements\nin this release, including, without limitation, those risks associated with\nour ability to execute on our commercialization strategy, the possibility that\nwe may be unable to raise sufficient funds necessary for our anticipated\noperations, our post-market clinical data collection activities, benefits of\nour products to patients, our expectations with respect to product development\nand commercialization efforts, our ability to increase market and physician\nacceptance of our products, potentially competitive product offerings,\nintellectual property protection, our ability to integrate acquired\nbusinesses, our expectations regarding anticipated synergies with and benefits\nfrom acquired businesses, and other risks and uncertainties described in our\nfilings with the SEC. Forward-looking statements speak only as of the date\nwhen made. Nuwellis does not assume any obligation to publicly update or\nrevise any forward-looking statements, whether due to new information, future\nevents or otherwise.\n\nFor further information, please contact:\n\nInvestor Relations: \nCORE IR\nir@nuwellis.com\n\nMedia Contact: \nCORE PR\nmedia@nuwellis.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/92c460b4-3e5c-4a6f-a33c-636a1520d076)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX992kY2","title":"Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer","author":"Globe Newswire","ticker":"NUWE","created":"2026-08-06T12:30:00.743Z","tickers":["NUWE"],"exchange":"NASDAQ","article_body":"MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE),\na medical technology company committed to delivering solutions for patients\nwith cardiorenal conditions, today announced the appointment of Dale Brady as\nPrincipal R&D Engineer. Brady brings more than 25 years of medical device\nleadership experience in research and development, operations, manufacturing,\nquality systems and commercialization, with a proven track record of advancing\ninnovative products from concept through commercial launch. As Principal R&D\nEngineer, Brady joins Nuwellis’ research and development team to advance its\nexisting and new product development programs.\n\n\"Dale's experience developing innovative medical technologies from concept\nthrough commercialization makes him an outstanding addition to our\norganization,\" said Mike McCormick, Nuwellis President and Chief Executive\nOfficer. \"As we continue to expand our product development pipeline and\nexecute on multiple strategic initiatives, Dale brings the technical depth,\noperational discipline, and hands-on leadership that will help accelerate\ninnovation while maintaining our focus on quality and execution.\"\n\nThroughout Brady’s career, he has successfully led multidisciplinary\nengineering teams and developed products from initial concept through\nregulatory submission, manufacturing scale-up and commercial launch across\nboth venture-backed startups and publicly traded medical device companies.\nMost recently, Brady served on the executive leadership teams of Peytant\nSolutions and Endogenex, where he directed engineering and operations\nactivities supporting commercialization and clinical development.\n\nPreviously, Brady spent nearly a decade at Osprey Medical leading development\nof next-generation cardiovascular technologies and digital monitoring systems,\nand held engineering leadership positions at Anulex Technologies and\nSpine-Tech. He is also an inventor or co-inventor on 10 issued U.S. patents\nand 16 pending patent applications. Brady holds a Master of Science in\nEngineering Management from the University of Alaska Fairbanks and a Bachelor\nof Science in Mechanical Engineering from the University of Minnesota.\n\nKim Anderson, Nuwellis Vice President, Research & Development, Quality and\nOperations, added: \"Dale is a tremendous addition to our engineering\norganization. He has a unique combination of deep technical expertise and\npractical experience leading product development in both entrepreneurial\nmedical device companies and publicly traded organizations. He is an ideal fit\nfor Nuwellis given his ability and expertise to advance products from concept\nthrough commercialization, while working effectively in resource-constrained\nenvironments. Dale will play a key role in leading many of our internal\nproduct development initiatives and strengthening our ability to execute\nmultiple strategic programs simultaneously.”\n\nAbout Nuwellis\nNuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to\ndelivering solutions for patients with cardiorenal conditions. The Company\ndevelops solutions designed to support patient care through monitoring,\ntherapy, and data-informed clinical decision-making across acute and chronic\ncare settings. Nuwellis’ portfolio includes commercially available and\ndevelopment-stage technologies addressing complex cardiorenal conditions, with\na focus on safety, precision, and scalability across patient populations. For\nmore information, visit www.nuwellis.com.\n\nForward-Looking Statements\nCertain statements in this release may be considered forward-looking\nstatements within the meaning of the Private Securities Litigation Reform Act\nof 1995, including without limitation, statements regarding the new market\nopportunities and anticipated growth in 2026 and beyond. Forward-looking\nstatements are predictions, projections and other statements about future\nevents that are based on current expectations and assumptions and, as a\nresult, are subject to risks and uncertainties. Many factors could cause\nactual future events to differ materially from the forward-looking statements\nin this release, including, without limitation, those risks associated with\nour ability to execute on our commercialization strategy, the possibility that\nwe may be unable to raise sufficient funds necessary for our anticipated\noperations, our post-market clinical data collection activities, benefits of\nour products to patients, our expectations with respect to product development\nand commercialization efforts, our ability to increase market and physician\nacceptance of our products, potentially competitive product offerings,\nintellectual property protection, our ability to integrate acquired\nbusinesses, our expectations regarding anticipated synergies with and benefits\nfrom acquired businesses, and other risks and uncertainties described in our\nfilings with the SEC. Forward-looking statements speak only as of the date\nwhen made. Nuwellis does not assume any obligation to publicly update or\nrevise any forward-looking statements, whether due to new information, future\nevents or otherwise.\n\nFor further information, please contact:\n\nInvestor Relations: \nCORE IR\nir@nuwellis.com\n\nMedia Contact: \nCORE PR\nmedia@nuwellis.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/92c460b4-3e5c-4a6f-a33c-636a1520d076)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-06T12:30:00.932086789Z","server_sent_at_ms":1786019400932},"received_at":"2026-08-06T12:30:01.763Z","source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340277/26106/en/nuwellis-strengthens-product-development-organization-with-appointment-of-dale-brady-as-principal-r-d-engineer.html"},"analysis":{"id":"100412","press_release_id":"111410","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Nuwellis appointed Dale Brady as Principal R&D Engineer to strengthen its product development organization and advance its pipeline programs.\n\nBrady brings over 25 years of experience in medical device R&D, operations, and commercialization, having previously held leadership roles at Peytant Solutions, Endogenex, and Osprey Medical.\n\nCEO Mike McCormick highlighted that Brady's technical depth and operational discipline will help accelerate innovation and execute on the company's strategic initiatives.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Nuwellis adds veteran R&D leadership to support product pipeline growth."},"keyFigures":null,"quotedText":"Dale's experience developing innovative medical technologies from concept through commercialization makes him an outstanding addition to our organization","namedEntities":{"people":[{"name":"Dale Brady","role":"Principal R&D Engineer"},{"name":"Mike McCormick","role":"President and Chief Executive Officer"},{"name":"Kim Anderson","role":"Vice President, Research & Development, Quality and Operations"}],"products":[],"companies":[{"name":"Nuwellis, Inc.","ticker":"NUWE"},{"name":"Peytant Solutions"},{"name":"Endogenex"},{"name":"Osprey Medical"},{"name":"Anulex Technologies"},{"name":"Spine-Tech"},{"name":"CORE IR","relationship":"investor relations"},{"name":"CORE PR","relationship":"media contact"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"The appointment of a Principal R&D Engineer, while beneficial for the product pipeline, is a functional operational hire rather than a C-level change or material corporate event."},"tickerRelevance":{"others":[],"primary":"NUWE"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"functional-hire","sectorWeight":"med-tech"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":1,"narrative":"Nuwellis appointed Dale Brady as Principal R&D Engineer to strengthen its product development organization and advance its pipeline programs.\n\nBrady brings over 25 years of experience in medical device R&D, operations, and commercialization, having previously held leadership roles at Peytant Solutions, Endogenex, and Osprey Medical.\n\nCEO Mike McCormick highlighted that Brady's technical depth and operational discipline will help accelerate innovation and execute on the company's strategic initiatives.","key_figures":null,"named_entities":{"people":[{"name":"Dale Brady","role":"Principal R&D Engineer"},{"name":"Mike McCormick","role":"President and Chief Executive Officer"},{"name":"Kim Anderson","role":"Vice President, Research & Development, Quality and Operations"}],"products":[],"companies":[{"name":"Nuwellis, Inc.","ticker":"NUWE"},{"name":"Peytant Solutions"},{"name":"Endogenex"},{"name":"Osprey Medical"},{"name":"Anulex Technologies"},{"name":"Spine-Tech"},{"name":"CORE IR","relationship":"investor relations"},{"name":"CORE PR","relationship":"media contact"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-06T20:47:36.938Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"functional-hire","sectorWeight":"med-tech"}},"durationMs":163059,"modelName":"glm-4.7"}}